In the year before COVID-19 struck, the molecular diagnostics and life sciences company Qiagen NV initiated several changes that not only helped it set a new strategic direction, but also as it transpired, manage a sound course through the pandemic that took hold in early 2020.
Company CFO and managing director Roland Sackers referred to those changes implemented by the Netherlands-based, New York-listed holding company as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?